Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure Bioscience inks co-marketing deal with SCIEX

The venture can deliver a powerful method to “industrialize” proteomics research, according to SCIEX director Mark Cafazzo.
Pressure Bioscience inks co-marketing deal with SCIEX
The new partners will together promote pressure cycling technology systems.

--UPDATE--

Pressure Bioscience (OTCMKT:PBIO) has agreed an exclusive co-marketing agreement with SCIEX, a life science analytical technologies group, which will see the new partners promote pressure cycling technology (PCT) systems.

The systems allow scientists to better extract proteins and other biological matter from cells, and that potentially yields superior biological insights.

Through the new relationship SCIEX says it will be uniquely positioned to address major challenge in complex sample preparation by marketing a complete solution.

Specifically, the agreement will see the PCT-HD system, developed by Pressure Bioscience, along with SCIEX analytic systems such as SWATH, TripleTOF, QTRAP and Triple Quad.

SCIEX highlighted that the combination of the technologies can allow proteome analysis results within 12 hours from the start of processing, which it says is much faster than current methods.

Mark Cafazzo, SCIEX director of academic and clinical research business, said the venture can deliver a powerful method to “industrialize” proteomics research.

“By partnering with PBI and adding the PCT technology to SCIEX next-generation proteomic solutions, we help scientists address the sample preparation challenges they face every day, especially when working with difficult tissue samples,” Cafazzo said.

 “The net result is more comprehensive protein quantitation from complex samples, increased productivity and higher quality results.

“This is an exciting step forward for the field of proteomics, one that offers the potential to make a great and lasting impact on the quality of human life.”

Meanwhile, Pressure Bioscience chief executive Richard Schumacher added: “Bringing the PCT platform into the research laboratory enables scientists to efficiently and reproducibly break apart tissue samples and greatly accelerate their processing.

“By combining these methods with SCIEX’s expertise and successful history in mass spectrometry system solutions, clinical researchers will be equipped to make major leaps forward in proteomic analysis, over the current limitations of traditional methods.”

News of the new tie-up comes after Pressure Bioscience yesterday lifted the bar on its fund raising.

The company told investors on Monday that it had increased the capacity of its equity offering up to US$6.25mln, from US$5mln, following the receipt of US$255,000 from a hedge fund in the fifth under the placement.

Most of the cash proceeds have been used to eliminate variable-rate convertible debt, which has in turn strengthened the group’s balance sheet.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use